Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

24 Nov 2014

Unique ability helps prolific bacterium to afflict humans, animals and even plants

New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism -- a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.

23 Nov 2014

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults.

21 Nov 2014

Excess fat in lungs may cause pulmonary fibrosis

Pulmonary fibrosis has no cure. It's caused by scarring that seems to feed on itself, with the tougher, less elastic tissue replacing the ever moving and stretching lung, making it increasingly difficult for patients to breathe.

20 Nov 2014

TSRI study examines body’s own response against chronic protein misfolding

“Protein misfolding” diseases such as cystic fibrosis and Alzheimer’s may be seriously exacerbated by the body’s own response against that misfolding, according to a new study led by scientists at The Scripps Research Institute.

20 Nov 2014

Common antimicrobial in household items causes liver fibrosis, cancer in mice

Triclosan is an antimicrobial commonly found in soaps, shampoos, toothpastes and many other household items. Despite its widespread use, researchers at University of California, San Diego School of Medicine report potentially serious consequences of long-term exposure to the chemical.

18 Nov 2014

Study finds that fat around heart closely associated with atrial fibrillation

Obesity is a known risk factor for atrial fibrillation, the most common heart rhythm disorder.

18 Nov 2014

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

18 Nov 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA.

12 Nov 2014

Salivary mucins protect teeth from cariogenic bacterium

Salivary mucins, key components of mucus, actively protect the teeth from the cariogenic bacterium, Streptococcus mutans, according to research published ahead of print in Applied and Environmental Microbiology. The research suggests that bolstering native defenses might be a better way to fight dental caries than relying on exogenous materials, such as sealants and fluoride treatment, says first author Erica Shapiro Frenkel, of Harvard University, Cambridge, MA.

11 Nov 2014

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Murdoch University researchers from the Centre for Comparative Genomics have received almost $800,000 in funding from the National Health and Medical Research Council to develop genetic drugs to treat rare diseases.

6 Nov 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announces that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as an orphan medicinal product.

4 Nov 2014

Epicure project: an interview with Frédéric Cren

Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.

3 Nov 2014

UW-Madison receives $8.3 million NIH grant to create new urological research center

The University of Wisconsin-Madison has been awarded an $8.3 million grant from the National Institutes of Health to create a research center focused on urological health.

29 Oct 2014

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan Holdings Limited, a UK company focused on the development of novel medicines based on calcium ion channel modulators, and Galapagos NV, a clinical stage biotech company focused on developing novel mode of action medicines, today announce that they have entered into a research collaboration in the area of osteoarthritis pain.

27 Oct 2014

Growth factor boosts natural defence against auto-immune diseases

Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis. A molecule called insulin-like growth factor-1 (IGF-1) boosts the body's natural defence against this 'friendly fire', scientists at the European Molecular Biology Laboratory in Monterotondo, Italy, have found.

25 Oct 2014

Aseptika launches Contactless Thermometer and Pulse Oximeter

With the winter flu and cold season almost upon us we can stock up and take some steps to prepare at home for this eventuality. Having a flu jab, eating well, getting lots of exercise and sleep, and maintain good personal hygiene all help in preventing flu and colds.

23 Oct 2014

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later.

22 Oct 2014

Fibrosis News and Research

Further Reading

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Unique ability helps prolific bacterium to afflict humans, animals and even plants

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

Excess fat in lungs may cause pulmonary fibrosis

TSRI study examines body’s own response against chronic protein misfolding

Common antimicrobial in household items causes liver fibrosis, cancer in mice

Study finds that fat around heart closely associated with atrial fibrillation

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Salivary mucins protect teeth from cariogenic bacterium

Murdoch University researchers receive NHMRC grant to develop genetic drugs for rare diseases

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Epicure project: an interview with Frédéric Cren

UW-Madison receives $8.3 million NIH grant to create new urological research center

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Growth factor boosts natural defence against auto-immune diseases

Aseptika launches Contactless Thermometer and Pulse Oximeter

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News